Table III.
Evaluation of Formulations
| Formulation | Phase transition (sol–gel) temperature (°C) at formulation pH | Viscosity (cP) at 20 rpm | Drug content (mg/ml) | Formulation pH | |
|---|---|---|---|---|---|
| At 20°C/formulation pH | At 34°C/pH 7.4 | ||||
| PL18FN | 32 ± 0.5 | 25 ± 3 | 6,618 ± 106 | 10.08 ± 0.12 | 7.44 ± 0.1 |
| AA03FN | – | 18 ± 3 | 2,423 ± 112 | 9.98 ± 0.10 | 4.44 ± 0.1 |
| A3P4FN | 31 ± 0.5 | 26 ± 2 | 6,863 ± 106 | 10.06 ± 0.16 | 4.42 ± 0.2 |
| A2P4FN | 30 ± 0.5 | 24 ± 2 | 2,307 ± 119 | 10.02 ± 0.15 | 4.51 ± 0.1 |
| A4P4FN | 31 ± 0.5 | 26 ± 3 | 9,436 ± 124 | 9.98 ± 0.12 | 4.37 ± 0.2 |
| A3P3FN | 32 ± 0.5 | 20 ± 2 | 3,095 ± 104 | 9.92 ± 0.15 | 4.43 ± 0.2 |
| A3P5FN | 28 ± 0.5 | 51 ± 4 | 12,662 ± 125 | 9.90 ± 0.11 | 4.52 ± 0.2 |
| 1% forskolin suspension | – | – | – | 9.88 ± 0.18 | 7.45 ± 0.1 |
Each value given in the table was calculated from n = 3 parallels and was given by the mean ± SD